What should you know about SMM myeloma?

Smoldering multiple myeloma, often called SMM, is an early plasma-cell disorder that needs specialist assessment and regular monitoring because it can sometimes develop into active multiple myeloma. Plasma cells are immune cells in the bone marrow that make antibodies. In SMM, testing shows an abnormal plasma-cell population or an excess of a related protein, but there is no evidence of the organ damage used to define active myeloma. The term does not describe a symptom or a cancer stage by itself; your haematology team interprets it using blood, urine, bone-marrow, and imaging results.

Many people with SMM feel well, and the condition may be found during tests for an unrelated concern. The main distinction from active multiple myeloma is whether the plasma-cell disorder is causing problems such as anaemia, kidney impairment, high calcium, or bone damage. These findings are assessed rather than assumed from the label alone. Your clinician may review blood counts, kidney function, calcium, antibody-related proteins, and imaging, and may recommend a bone-marrow examination. Results can change over time, so one set of tests does not determine every future decision.

SMM is different from active multiple myeloma, which may require treatment. If active disease is diagnosed, options can include systemic medicines, targeted therapy, or other specialist approaches. The separate guide to Multiple Myeloma explains that condition in more detail.

Keep the follow-up appointments arranged by your haematology team. Monitoring commonly includes repeat blood and urine tests, symptom review, and imaging when clinically indicated. Bring a list of medicines and supplements, and mention new infections, reduced appetite, unusual tiredness, changes in urination, or persistent pain. Do not stop prescribed treatment or start supplements intended to affect calcium or bone health without discussing them with your clinician.

Ask whether your results show any feature that changes the monitoring plan, whether imaging is needed, and which service to contact between appointments. If your care team recommends treatment because the disease has become active or your risk assessment has changed, they may discuss chemotherapy, targeted therapy, or a cellular treatment pathway. Supportive options may include Bone-Strengthening Therapy when appropriate.

Contact your oncology or haematology team promptly about persistent or worsening bone pain, marked weakness, breathlessness, repeated infections, unexplained bruising, reduced urine, or new swelling. These changes have several possible causes, but they may signal anaemia, infection, kidney problems, or other complications that need assessment.

Seek urgent medical help for severe sudden pain, confusion, fainting, chest pain, difficulty breathing, or very little urine. Do not wait for a routine monitoring visit when symptoms are severe or rapidly worsening.

Useful questions include: Which test results support the SMM diagnosis? What findings would indicate active multiple myeloma? How often should I have blood, urine, or imaging tests? Which symptoms should prompt a same-day call? Should I change exercise, dental care, or other daily activities? Would a second haematology opinion or a clinical assessment at a specialist centre help me understand my options?